Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Mar;21(2):110-5.
doi: 10.1097/CCO.0b013e328322cf49.

The role of maintenance chemotherapy in advanced nonsmall cell lung cancer

Shadia I Jalal  1 , Foluso O Ademuyiwa, Nasser H Hanna
Affiliations
Review

The role of maintenance chemotherapy in advanced nonsmall cell lung cancer

Shadia I Jalal et al. Curr Opin Oncol. 2009 Mar.

Abstract

Purpose of review: Advanced nonsmall cell lung cancer (NSCLC) remains a therapeutic challenge. Traditional chemotherapy provides response rates of about 20-40% and median survivals of 8-10 months. The outcome of patients presenting at an advanced stage is therefore disappointing. In order to improve patients' outcomes, there has been a renewed interest in evaluating the role of maintenance or consolidation chemotherapy or both. Therefore, this review is timely and also relevant to clinical practice.

Recent findings: Thirteen randomized clinical trials have reported that consolidation or maintenance therapy or both improves progression free survival in patients with advanced NSCLC who have achieved disease control following their initial therapy. This does not translate into survival benefits in the same patient populations. Furthermore, prolonged therapy results in more treatment-related toxicity without improvements in quality of life as documented in 11 of these trials. We summarize the current data and perspectives of consolidation/maintenance therapy in patients with advanced NSCLC.

Summary: Completed trials evaluating consolidation or maintenance therapy or both in patients with advanced NSCLC consistently demonstrate that this strategy will improve progression free survival but not overall survival. Administering maintenance or consolidation therapy to patients with advanced NSCLC to improve progression free survival alone is not recommended.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

MeSH terms

Substances